Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD4916 · 1 trial · 1 indication
The safety and tolerability of AZD4916 following oral administration of single-ascending doses and multiple-ascending doses to healthy participants (including Japanese and Chinese) will be assessed.
| Arm | Type | Description |
|---|---|---|
| AZD4916 | EXPERIMENTAL | Parts 1a and 2a participants will receive a single oral dose of AZD4916 on Day 1. Parts 1b and 2b participants will receive a single oral dose of AZD4916 on Day 1 and multiple doses of AZD4916 on Days 4 through 17. |
| Placebo | PLACEBO_COMPARATOR | Parts 1a and 2a participants will receive a single oral dose of placebo on Day 1. Parts 1b and 2b participants will receive a single dose placebo on Day 1 and multiple doses of placebo on Days 4 through 17. |
| Name | Type | Description |
|---|---|---|
| AZD4916 | DRUG | AZD4916 will be administered as oral solution. |
| Placebo | OTHER | Placebo will be administered as oral solution. |
Main Inclusion Criteria: * Healthy male and female participants with suitable veins for cannulation or repeated venipuncture. * All females must have negative pregnancy test and females of childbearing potential must not be lactating and must agree to use an approved method of highly effective cont...
AZD4916 is an investigational small molecule being studied in healthy participants. It is currently in Phase 1 clinical development, with a single active trial evaluating its safety and pharmacokinetics. The drug is not approved for any indication and remains under investigation.
AZD4916 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker symbol AZN. The company is conducting a Phase 1 clinical trial to investigate the drug's safety and pharmacokinetics in healthy volunteers.
AZD4916 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to study the safety and pharmacokinetics of single and multiple ascending doses of the drug.
AZD4916 is being studied in one active Phase 1 clinical trial, registered under the identifier NCT06951880. The trial is titled 'A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy Volunteers' and is recruiting participants in the United States and United Kingdom.
Yes, AZD4916 is being studied in healthy volunteers. The Phase 1 clinical trial NCT06951880 is a placebo-controlled study enrolling 160 healthy participants aged 18 years and older. The trial is randomized but not double-blinded, and it is currently recruiting in the United States and United Kingdom.